MedPacto 2026 Q1: Revenue Up but Net Loss Widens; Pipeline Progresses

Consolidated Q1 2026 revenue 1,323M KRW (up 208% YoY from 430M), net loss 3,760M KRW (widened from 3,359M KRW)
Cash and equivalents 8.8B KRW, short-term financial instruments 28.96B KRW, total liquidity 37.8B KRW, debt ratio 6.53%
Lead pipeline Vactosertib: phase 2b/3 with MSD Keytruda for colorectal cancer, phase 1/2 monotherapy for osteosarcoma in US and Korea
Follow-on candidates MP010 (TME-targeted) and MP2021 (bone/autoimmune) in preclinical stage; MP010 showed efficacy in pancreatic cancer model
Consolidated R&D expenses 3.18B KRW (2.42% of revenue), up from 2.62B in prior year, funding ongoing trials and preclinical studies
Standalone revenue 1.3B KRW (pharma products 1.0B, genomics 0.8B, distribution 2.3B), operating loss 3.93B, net loss 3.76B
Loss per share 110 KRW (vs 100 KRW in prior year), equity 42.6B KRW, shares outstanding 34,275,121, stock options outstanding 685,500
No dividend or share buyback/s cancellation; no material contingent liabilities